5 hours ago
1
Grandbrothers/iStock Editorial via Getty Images
Despite an FDA request to halt shipments, Sarepta Therapeutics (NASDAQ:SRPT) announced late Friday that the company will continue to ship its gene therapy Elevidys, developed with Roche (OTCQX:RHHBY), for ambulant patients with Duchenne muscular dystrophy, a rare neuromuscular disorder.
The
English (US) ·